GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Tisotumab vedotin (Tivdak), IV injection

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Tivdak - labeled renal guidance

Product / population
Tisotumab vedotin (Tivdak), IV injection
Renal method
Cockcroft-Gault CrCl, mL/min
Source revision
DailyMed SPL version 11, posted Oct 26, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Tivdak - product and source limitations

The result does not establish dosing in severe impairment or dialysis.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Tivdak - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Tisotumab vedotin (Tivdak), IV injection

Renal method: Cockcroft-Gault CrCl, mL/min
Source date: DailyMed SPL version 11, posted Oct 26, 2026
Retrieved: 2026-11-07

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 12.3 Pharmacokinetics

The exposure analysis found no clinically important differences with mild or moderate impairment at Cockcroft-Gault CrCl 30 to below 90 mL/min. The result does not establish dosing in severe impairment or dialysis.

RDM74-tivdak-official-1 · Source locator: Renal guidance: 12.3 Pharmacokinetics

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9fe3f32-4219-466e-acb9-3f609b4f4df1
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl, mL/min
Source date/version
DailyMed SPL version 11, posted Oct 26, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
7b1512d00029c80cfcb2177f306cc0075e182eb191e23be3409875c00559b2a8

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-tivdak&s1=RDM74-tivdak-official&h1=9c407a80ed05c2c801d0902fc1580d33ba7974d93facdf5d1562c6e4ccf1de41

Top